Clinical Trials

Inclusion Criteria:

• Admitted to an intensive care unit (ICU) with pathogen associated shock defined as:
  • The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation;
  • Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing.
• Male or non-pregnant female adult.
• At least 18 years of age at time of enrollment.
• Within 72 hours of admission to the ICU.

Exclusion Criteria:

• Pregnant or breast feeding.
• Anticipated transfer to another hospital (that is not a study site) within 72 hours for any reason.
• Not anticipated to survive more than 24 hours.
• Allergy to heparin sodium.
• Patients who cannot tolerate placement of double-lumen catheter.
• High risk of bleeding (platelet count < 50mm^3 or International normalized ratio > 1.5).
• Inability to tolerate extra-corporeal therapy (defined as MAP < 65 despite fluids and vasopressors).
• Advanced cancer (defined as stage IV).
• Unable to obtain informed consent from either patient or legally authorized representative.
• Hypotension and volume depletion due to etiologies other than sepsis.
• Neutropenia with an absolute neutrophil count < 500mm^3.

Eligibility last updated 5/10/22. Questions regarding updates should be directed to the study team contact.